Dr Mohamed Bouattour

Spécialité

Onco-hépatologie (thématique, carninome hépatocellulaire, cholangiocarcinome, cancers hépatiques rare)

Hôpital

Hôpital Beaujon (Clichy)

Derniers articles

• Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. (1 août 2026)
• Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study. (6 juil. 2026)
• Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. (11 juin 2026)
• Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma. (11 juin 2026)
• Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis. (12 mai 2026)